As the AstraZeneca share price slides, I’d buy

The AstraZeneca share price has been under pressure due to temporary headwinds, but these will not last forever and growth will return.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since reaching an all-time high of around 9,200p in the middle of July last year, the AstraZeneca (LSE: AZN) share price has fallen by approximately 22%. I think this is unwarranted. As such, I would invest £5,000 in the pharmaceutical giant today to take advantage of this market opportunity. 

AstraZeneca share price opportunity

In the middle of last year, AstraZeneca was riding high after it emerged that the group’s coronavirus vaccine was precisely what the world needed. A cheap, effective jab that could be rolled out across the globe. 

Unfortunately, the company was only able to bask in its success for a few months. This year, the group has faced mounting criticism from critical partners such as the European Union. The EU has attacked the organisation for not living up to its contractual obligations to supply vaccines. Meanwhile, the vaccine has been linked to very, very rare blood clots. 

But I don’t think these issues should put investors off the business. Astra pledged from the outset not to make excess profits on the jab. It has forgone nearly £15bn in revenue so far thanks to this commitment.

Therefore, I don’t think it will affect the group too much if countries bypass its jab favouring others. On the other hand, a sudden boom in demand won’t have a considerable positive impact on the firm’s bottom line. 

As such, I think it could be an excellent time to take advantage of the swooning AstraZeneca share price to buy into the company’s long-term growth story. Indeed, there’s far more to the business than just its Covid vaccine. 

As well as vaccines, Astra also manufactures cancer drugs, diabetes treatments and respiratory drugs, among others. I think these will be the core areas of growth for the group over the next few years. Put simply, I’m pretty happy to look past the company’s current vaccine troubles and focus on its long-term potential. 

Risks and challenges

That’s not to say that the group does not face any risks and challenges as we advance. In the past, the company has struggled to invest enough in new treatments. Management has tried to rectify this, but it could remain an issue. There are plenty of other enterprises out there willing to spend billions of dollars every year developing new products. Astra needs to keep up, or it could be left behind. 

At the same time, legal threats and challenges are a persistent threat to the pharmaceutical industry. Astra is probably more exposed now due to its coronavirus vaccine commitments. A lawsuit from the EU could cost the company a significant sum to fight.

These risks aside, I’m incredibly excited about what the future holds for the AstraZeneca share price. That’s why I would take advantage of the recent weakness in the shares to build a position worth £5k. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »